Prolonged ventricular pause associated with ticagrelor use: A case report
- PMID: 34721870
- PMCID: PMC8543052
- DOI: 10.1002/ccr3.5017
Prolonged ventricular pause associated with ticagrelor use: A case report
Abstract
Case: We report a case of a 76-year-old female who presented with non-ST elevation myocardial infarction and developed a 22-second ventricular pause with ticagrelor that did not recur after shifting to clopidogrel. Based on the Naranjo algorithm, the likelihood that our patient's prolonged ventricular pause was due to ticagrelor exposure was probable.
Conclusion: Ticagrelor use is associated with prolonged ventricular pauses, warranting close monitoring, particularly during the first week of therapy.
Keywords: adverse drug reaction; ticagrelor; ventricular pause.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Figures
Similar articles
-
The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction.Int J Cardiol. 2019 Jul 15;287:19-26. doi: 10.1016/j.ijcard.2019.04.010. Epub 2019 Apr 3. Int J Cardiol. 2019. PMID: 30979602
-
A Case of Ticagrelor-Induced Sinus Pause.Cureus. 2023 Jul 13;15(7):e41821. doi: 10.7759/cureus.41821. eCollection 2023 Jul. Cureus. 2023. PMID: 37575834 Free PMC article.
-
Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI).JACC Cardiovasc Interv. 2020 Oct 12;13(19):2220-2234. doi: 10.1016/j.jcin.2020.08.007. JACC Cardiovasc Interv. 2020. PMID: 33032710 Clinical Trial.
-
Progress in the clinical effects and adverse reactions of ticagrelor.Thromb J. 2024 Jan 10;22(1):8. doi: 10.1186/s12959-023-00559-3. Thromb J. 2024. PMID: 38200557 Free PMC article. Review.
-
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.J Thromb Thrombolysis. 2018 Oct;46(3):299-303. doi: 10.1007/s11239-018-1706-2. J Thromb Thrombolysis. 2018. PMID: 29934940
References
-
- Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non‐ST‐segment elevation acute coronary syndrome: primary results of the DISPERSE‐2 tri. J Am Coll Cardiol. 2007;50(19):1844‐1851. 10.1016/j.jacc.2007.07.053 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources